• Aminov RI, Walker AW, Duncan SH, Harmsen HJM, Welling GW & Flint HJ (2006) Molecular diversity, cultivation, and improved detection by in situ hybridization of a dominant group of human gut bacteria related to Roseburia spp. or Eubacterium rectale. Appl Environ Microb 72: 63716376.
  • Benus RF, Harmsen HJ, Welling GW, Spaniersberg R, Zijlstra JG, Degena JE & Van Der Werf TS (2010) Impact of digestive and oropharyngeal decontamination on the intestinal microbiota in ICU patients. Intens Care Med 36: 13941402.
  • Chapman MAS, Grahn MF, Boyle MA, Hutton M, Rogers J & Williams NS (1994) Butyrate oxidation is impaired in colonic mucosa of sufferers of quiescent ulcerative colitis. Gut 35: 7376.
  • Costello AJ, Murphy JL, Wootton SA, Rucker JT, Kirby GA & Hunter JO (1994) The effect of elemental diet on stool output in irritable bowel syndrome. Proc Nut Soc 53: 223A.
  • Duncan SH, Louis P & Flint HJ (2004) Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl Environ Microb 70: 11361142.
  • Fite A, Macfarlane CT, Cummings JH, Kong FC, Furrie E & Macfarlane S (2004) Identification and quantification of mucosal and faecal desulfovibrios using real time polymerase chain reaction. Gut 53: 523529.
  • Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ & Brummer RJ (2008) Review article: the role of butyrate in colonic function. Aliment Pharm Therap 27: 104119.
  • Harvey RF & Bradshaw JM (1980) A simple index of Crohn's disease activity. Lancet 1: 514.
  • Hunter JO (1991) Food allergy or enterometabolic disorder? Lancet 338: 495496.
  • Johnson T, MacDonald S, Hill SM, Thomas A & Murphy MS (2006) Treatment of active Crohn's disease in children using partial enteral nutrition with a liquid formula: a randomised controlled trial. Gut 55: 306307.
  • King TS, Woolner JT & Hunter JO (1997) Dietary treatment of Crohn's disease. Aliment Pharm Toxicol 11: 1731.
  • Lane DJ (1991) 16S/23S rRNA sequencing. Nucleic Acid Techniques in Bacterial Systematics E (StackebrandtE & GoodfellowMN, eds), pp. 115147. Wiley, Chichester.
  • Levine J, Ellis CJ, Furne JK, Springfield J & Levitt MD (1998) Faecal hydrogen sulfide production in ulcerative colitis. Am J Gastroenterol 93: 8387.
    Direct Link:
  • Loubinoux J, Bronowscki J-P, Pereira IAC, Mougenel J-L & Faou AEL (2002) Sulphate-reducing bacteria in human feces and their association with inflammatory bowel disease. FEMS Microbiol Ecol 40: 107112.
  • Louis P & Flint HJ (2009) Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 294: 18.
  • Louis P, Young P, Holtrop G & Flint HJ (2009) Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA: acetate CoA-transferase gene. Environ Microbiol, in press 12: 304314.
  • Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J & Bjarnason I (1996) Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38: 365375.
  • Mai V & Draganov PV (2009) Recent advances and remaining gaps in our knowledge of associations between gut microbiota and human health. World J Gastroentero 15: 8185.
  • Marquet P, Duncan S, Chassard C, Bernalier-Donadille A & Flint HJ (2009) Lactate has the potential to promote hydrogen sulphide formation in the human colon. FEMS Microbiol Lett 299: 128134.
  • Pitcher MCL & Cummings JH (1996) Hydrogen sulphide: a bacterial toxin in ulcerative colitis? Gut 39: 14.
  • Roediger WEW, Moore J & Babidge W (1997) Colonic sulphide in pathogenesis and treatment of ulcerative colitis. Digest Dis Sci 42: 15711579.
  • Sartor RB (2006) Mechanisms of disease: pathogenesis of Crohns disease and ulcerative colitis. Nat Clin Pract Gastr 3: 390407.
  • Sartor RB (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134: 577594.
  • Schofield WN (1985) Predicting basal metabolic rate: new standards and review of previous work. Hum Nutr-Clin Nutr 39: 541.
  • Smith S, Shaw J & Nathwani D (2008) Nitazoxanide for cryptosporidial infection in Crohn's disease. Gut 57: 11791180.
  • Sokol H, Pigneur B, Watterlot L et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn's disease patients. P Natl Acad Sci USA 105: 1673116736.
  • Tazoe H, Otomo Y, Kaji I, Tanaka R, Karaki SI & Kuwahara A (2008) Roles of short chain fatty acid receptors, GPR41 and GPR43 on colonic functions. J Physiol Pharmacol 59 (suppl 2): 251262.
  • Van Der Waiij LA, Kroese FG, Visser A, Nelis GF, Westerveld BD & Jansen PC (2004) Immunoglobulin coating of faecal bacteria in inflammatory bowel disease. Eur J Gastroen Hepat 16: 669674.
  • Whelan K, Judd PA, Preedy VR, Simmering R, Jann A & Taylor MA (2005) Fructooligosaccharides and fiber partially prevent the alterations in fecal microbiota and short-chain fatty acid concentrations caused by standard enteral formula in healthy humans. J Nutr 135: 18961902.
  • Willis CL, Cummings JH, Neale G & Gibson GR (1997) Nutritional aspects of dissimilatory sulphate reduction in the human large intestine. Curr Microbiol 35: 294298.
  • Yin L, Laevsky G & Giardina C (2001) Butyrate suppression of colonocyte NF-B activation and cellular proteasome activity. J Biol Chem 276: 4464144646.